Earnings Ahead

NBIX - Neurocrine Biosciences Inc.

95.56 1.54 1.64

  1. Home
  2. Healthcare
  3. NBIX
Neurocrine Biosciences Inc.

Neurocrine Biosciences Inc.

About

Profile

Neurocrine’s management team participates in industry conferences providing presentations on company updates and progress on research and development activities. The company conducts webcasts and conference calls for these conferences and provides finan

Headquarters

San Diego, California, United States

Intraday

High
-
Low
-

52-week

High
-
Low
-

NBIX



 
...

Available for logged in users only.



The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.
  • Neurocrine Biosciences Non-GAAP EPS of $1.54 beats by $0.03, revenue of $515.2M misses by $3.19M
  • Neurocrine Biosciences Q4 2023 Earnings Preview
  • Big Pharma earnings season in spotlight amid positive sentiment
  • Goldman says these stocks with weak pricing power can outperform
  • Biogen, Neurocrine, and more are Bairds top picks for biotech in 2024
  • Bristol-Karuna deal: What other biotechs might be in M&A crosshairs?
  • Top overweight stocks with high growth and low volume - MS
  • Citi starts Neurocrine at neutral, sees stock as fairly valued
  • Neurocrine gets FDA breakthrough therapy status for crinecerfont
  • The most crowded pharma longs and shorts, according to UBS
  • Neurocrine Biosciences executive discloses sale of over 10K shares
  • Neurocrine settles all patent disputes related to movement disorder therapy
  • Neurocrine reports Phase 2 study failures for two drug candidates
  • Neurocrine Biosciences Non-GAAP EPS of $1.54 beats by $0.21, revenue of $498.8M beats by $19.77M
  • Neurocrine Biosciences Q3 2023 Earnings Preview
  • Neurocrine says new Ingrezza version is under FDA review
  • Neurocrine gains after Phase 3 win for genetic disorder drug
  • Neurocrine releases new data on Ingrezza for Huntington's disease chorea
  • Neurocrine nabs FDA label expansion for Ingrezza
  • Neurocrine Biosciences Non-GAAP EPS of $1.25 beats by $0.13, revenue of $452.7M beats by $4.72M

Earnings History

Date EPS / Forecast Revenue / Forecast
February 11, 2022 -0.08 / 0.671 312M / 317.93M
November 1, 2021 0.23 / 0.5568 296M / 297.83M
August 3, 2021 0.43 / 0.5019 288.9M / 273.19M Beat!
May 5, 2021 0.33 / 0.5276 236.6M / 250.67M
February 4, 2021 3.58 / 0.6014 247.9M / 260.45M
November 9, 2020 -0.62 / -0.0194 258.5M / 282.7M
August 3, 2020 0.81 / 0.61 302.4M / 261.31M Beat!
May 6, 2020 0.39 / 0.54 237.1M / 226.53M Beat!
February 4, 2020 0.35 / 0.78 244.1M / 231.54M Beat!
November 4, 2019 0.56 / 0.66 222.09M / 211.97M Beat!
July 29, 2019 0.54 / 0.19 183.58M / 161.79M Beat!
April 29, 2019 -1.12 / -0.78 138.4M / 136.76M Beat!
February 5, 2019 0.19 / 0.18 131.49M / 132.34M
Date Price Open High Low Vol Change
Dec 2 152.48 151.13
153.79
150.84
853K 1.06%
Dec 1 150.88 152.38
153.29
149.58
704K -0.84%
Nov 28 152.16 152.78
153.7
150.41
501K 0.38%
Nov 26 151.58 146.75
153.54
146
1.7M 5.61%
Nov 25 143.53 141.67
144.75
140.67
632K 1.61%
 
Nov 24 141.25 142.02
143.51
139.27
1.2M -0.41%
Nov 21 141.83 140.24
144.83
139.72
968K 2.05%
Nov 20 138.98 138.72
141.07
137.83
798K 0.67%
Nov 19 138.06 140.22
140.22
137.02
1.1M -0.41%
Nov 18 138.63 142.99
145.08
138.43
1.3M -3.43%
Nov 17 143.56 144.66
145.9
142.44
857K -0.9%
Nov 14 144.86 142.99
146.38
142.99
643K 0.49%
Nov 13 144.16 146.01
148.84
143.91
923K -1.83%
Nov 12 146.85 147.4
148.04
145.41
1.2M -0.3%
Nov 11 147.29 147.5
149.42
145
1.4M -1.82%
Nov 10 150.02 152.97
154.1
146.02
964K -1.54%
Nov 7 152.37 154.25
154.5
148.97
1.4M -1.57%
Nov 6 154.8 153.86
155.64
152.86
944K 0.68%
Nov 5 153.75 147.7
157.67
147.7
2.9M 7.37%
Nov 4 143.19 142.35
143.87
140.82
745K 0.87%
Nov 3 141.96 142.62
144.98
139.46
764K -0.87%
Oct 31 143.21 138.04
143.47
137.07
1.3M 3.75%
Oct 30 138.04 137.41
140.19
136.51
900K 0.01%
Oct 29 138.02 140
144.3
133.61
3.0M -6.35%
Oct 28 147.38 147.38
149.98
146.63
1.4M -1.05%
Oct 27 148.94 145
149.33
144.94
965K 3.43%
Oct 24 144 143.6
144.42
142.2
636K 0.23%
Oct 23 143.67 141.89
144.65
141.73
675K 1.56%
Oct 22 141.47 143.43
143.68
141.26
593K -0.83%
Oct 21 142.65 141.79
142.97
141.29
512K 0.93%
Oct 20 141.33 141.08
142.59
138.79
674K 0.89%
Oct 17 140.09 137.52
140.47
137.02
977K 1.87%
Oct 16 137.52 138.13
140.73
136.7
798K -0.15%
Oct 15 137.73 137.19
139.46
137
651K 0.36%
Oct 14 137.23 137.65
138.6
135.78
599K -0.09%
Oct 13 137.35 136.85
139.56
135.63
671K 0.53%
Oct 10 136.63 139.29
139.35
135.8
494K -1.33%
Oct 9 138.47 139.94
140.53
138.39
608K -0.44%
Oct 8 139.08 137.87
139.74
136.1
684K 1.52%
Oct 7 137 139.8
141.14
135.96
855K -1.74%
Oct 6 139.43 137.21
140.65
136.6
899K 1.75%
Oct 3 137.03 137.3
137.8
135.76
1.2M 0.21%
Oct 2 136.74 136.32
137.63
135.59
937K -0.19%
Oct 1 137 140.12
141.36
136.61
1.4M -2.41%
Sep 30 140.38 140.28
141.69
137.97
1.2M 0.08%
Sep 29 140.27 141.55
141.97
139.16
903K -1.22%
Sep 26 142 141.86
142.08
139.9
980K 0.79%
Sep 25 140.89 145.29
145.61
140.52
1.1M -3.94%
Sep 24 146.67 146.25
148
145.61
652K 0.18%
Sep 23 146.4 146
147.56
145.67
665K -0.15%
Sep 22 146.62 145
147.73
144.37
701K 0.96%
Sep 19 145.23 146.32
146.32
143.57
1.7M -0.3%
Sep 18 145.66 143.86
146.03
143.34
789K 2.05%
Sep 17 142.73 141.67
143.39
141.18
612K 1.30%
Sep 16 140.9 140.44
141.02
139.25
781K 0.33%
Sep 15 140.44 141.73
141.81
139.38
634K -1.01%
Sep 12 141.87 142.44
144.04
141.73
486K -1.2%
Sep 11 143.6 141.5
143.82
141.5
675K 1.66%
Sep 10 141.25 144.35
145.16
140.56
767K -2.03%
Sep 9 144.17 143.5
144.21
141.78
570K 0%